Biogen Idec Sales Of Avonex Dip In U.S. As Tysabri Gains Ground
This article was originally published in The Pink Sheet Daily
Review of acquisition bids for the firm could take “a number of months,” CEO Mullen reports.
You may also be interested in...
Activist investor Carl Icahn is among those interested in the biotech.
The highly restricted Tysabri risk management program tipped the risk-benefit scale in Biogen Idec/Elan’s favor.
Elan reports early data on uptake of the MS therapy, but says it is too early to tell how many enrollees will convert to patients treated.